All News

New data highlight digital dementia risk scores, plasma p-tau217 prediction, and patient-centered endpoints in Alzheimer disease research.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

Learn how primary care spots early hearing loss, flags urgent red symptoms, and boosts hearing-aid use to protect cognition and quality of life.

ACP updates RSV vaccine guidance: adults 75+ get a one-time protein subunit shot; higher-risk ages 60–74 may consider it to prevent hospitalization.

HIV specialist Jürgen Rockstroh, MD, discusses the importance of PrEP being more accessible through primary care physicians.

New real-world evidence links GLP-1RAs to lower acute care use and fewer treatment escalations than topiramate for chronic migraine.

Review key updates to the Dietary Guidelines for Americans to support patient counseling, nutritional assessments, and evidence-based interventions.

75.5% of pediatric food-allergic patients possess multiple concurrent allergies across three distinct clinical clusters, underscoring the importance of expanded allergy screening.

GLP‑1 therapy reduces asthma flare-ups in overweight non‑diabetics, suggesting a promising add-on for obesity-related asthma care.

FDA approves DESMODA, a ready-to-use desmopressin acetate oral solution, enabling precise titration for central diabetes insipidus with key hyponatremia warnings.

In JAMA, Christakis, MD, MPH exposes IDD mental health gaps—better screening, counseling access, and training for disabilities.

FDA approves dupilumab for allergic fungal rhinosinusitis ages 6+, cutting sinus blockage, polyps and smell loss while sharply reducing repeat surgery and steroid use.

In a phase 2 trial in China, UBT251 led to up to 19.7% mean weight loss at 24 weeks vs 2.0% with placebo in adults with overweight or obesity.

Swallowable gastric balloon, approved by the FDA, provides a non-invasive, surgery-free weight loss solution for patients with a BMI between 30 and 40.

In the REDEFINE 4 trial, CagriSema led to 23% weight loss at 84 weeks but did not demonstrate noninferiority to tirzepatide 15 mg in adults with obesity.

Explore new epinephrine options—nasal spray and sublingual film—designed to boost carry-and-use rates and treat anaphylaxis faster.

Learn severe anaphylaxis warning signs, key risk factors and how to recognize infant reactions—plus when to use epinephrine and seek ER care.

Learn why epinephrine stops anaphylaxis fast, when a second dose matters, and who can safely monitor at home after treatment.